Siupsinskiene Nora, Adamonis Kestutis
Clinic of Othorhinolaryngology, Kaunas University of Medicine Hospital, Eiveniu 2, 3007 Kaunas, Lithuania.
Medicina (Kaunas). 2003;39(1):47-55.
The aim of the study was to evaluate the merit of empiric omeprazole therapy in patients with suspected laryngopharyngeal reflux (LPR), to determine the optimal dose and duration of diagnostic test, to compare the diagnostic value of upper gastrointestinal (GI) endoscopy and omeprazole test (OT). One hundred out-patients with posterior laryngitis and more than one atypical symptom of LPR, aged 14-68 years were treated with omeprazole for 4 weeks (clinical group). According to received omeprazole dose (20 mg, 40 mg, > 40 mg), three clinical subgroups were selected. Twenty patients treated only with life style modifications and diet composed dietary group. At the entry to the study, a symptom questionnaire (5 laryngeal and 3 esophageal scored from 0 to 3 points), well being in general (W-B(VAS) on 100-mm VAS scale), videolaryngoscopy, upper endoscopy, and voice assessment (4 voice range profile parameters and overall vocal dysfunction degree (VDD)) were completed. Total symptom index (TSI) was calculated multiplying sum of symptoms severity score by number of presented symptoms. Normal values of efficacy parameters were obtained from 113 healthy voice subjects (control group). Patients were evaluated twice during the treatment: after 1-2 weeks and after 4-5 weeks. Patients were confirmed as responders, if TSI improved at least 50%, and patients were satisfied with results. According to our data, the 1st control assessment showed significant improvement on symptoms, laryngoscopy scores, VDD, and W-B(VAS) only for clinical group patients (p<0.05). Responders rate also was advantageous for the clinical group patients in comparison to the dietary group (36.0% vs. 15%). The second control assessment showed significantly better results for the clinical group patients in comparison to the 1st (p<0.05 2nd vs. the 1st). Sixty five percent of them (65/100) were classified as responders (p<0.05). The better results were in patients receiving omeprazole more than 20 mg daily. Erosive esophagitis during upper GI endoscopy was found for 21.0% (21/100) clinical group patients, 18 of them were responders to omeprazole 4-week test (accuracy of OT with regard to confirmed diagnosis with upper endoscopy was 85.7%). At week 4, efficacy parameters were not in normal range. We concluded that short-term treatment with omeprazole might be useful in confirming the clinically based diagnosis of laryngopharyngeal reflux.
本研究的目的是评估经验性使用奥美拉唑治疗疑似喉咽反流(LPR)患者的价值,确定诊断性试验的最佳剂量和持续时间,比较上消化道(GI)内镜检查和奥美拉唑试验(OT)的诊断价值。100例年龄在14 - 68岁、患有后喉炎且有不止一种LPR非典型症状的门诊患者接受了4周的奥美拉唑治疗(临床组)。根据接受的奥美拉唑剂量(20 mg、40 mg、>40 mg),选择了三个临床亚组。20例仅接受生活方式调整和特定饮食治疗的患者组成饮食组。在研究开始时,完成了一份症状问卷(5项喉部症状和3项食管症状,评分从0到3分)、总体健康状况(100毫米视觉模拟量表上的W - B(VAS))、视频喉镜检查、上消化道内镜检查以及嗓音评估(4项嗓音音域轮廓参数和总体嗓音功能障碍程度(VDD))。通过将症状严重程度评分总和乘以出现的症状数量来计算总症状指数(TSI)。从113名健康嗓音受试者(对照组)获得疗效参数的正常值。在治疗期间对患者进行两次评估:1 - 2周后和4 - 5周后。如果TSI改善至少50%且患者对结果满意,则患者被确认为有反应者。根据我们的数据,第一次对照评估显示仅临床组患者的症状、喉镜评分、VDD和W - B(VAS)有显著改善(p<0.05)。与饮食组相比,临床组患者的有反应者率也更高(36.0%对15%)。第二次对照评估显示临床组患者的结果明显优于第一次(第二次对第一次,p<0.05)。其中65%(65/100)被归类为有反应者(p<0.05)。每日接受超过20 mg奥美拉唑治疗的患者结果更好。上消化道内镜检查发现临床组患者中有21.0%(21/100)患有糜烂性食管炎,其中18例对奥美拉唑4周试验有反应(OT对于经上消化道内镜确诊的诊断准确性为85.7%)。在第4周时,疗效参数未处于正常范围内。我们得出结论,短期使用奥美拉唑治疗可能有助于证实基于临床的喉咽反流诊断。